A HbA1c or A1c test is used by doctors and healthcare professionals to measure your average blood sugar level over the last 2-3 months. The test result is used to diagnose, monitor, and manage treatment decisions for diabetes.
HbA1c is measured as a percentage (%).
In general, a higher HbA1c indicates a higher risk of long-term diabetes complications. If you have either type 1 or type 2 diabetes, your doctor will check your HbA1c levels to decide on the best treatment plan for you, and help you set a target to lower your HbA1c.
A healthy HbA1c is below 5.7%
HbA1c between 5.7-6.4% indicates prediabetes. This means you are at risk of developing diabetes
HbA1c of 6.5% or above indicates diabetes
If you do not have diabetes, HbA1c of 5.9% in the first 15 weeks of pregnancy may mean you are at higher risk for gestational diabetes.
HbA1c does not give a full picture of your blood sugar levels. It does not account for the ups and downs of your blood sugar within a day or show patterns in your blood sugar over time. HbA1c also can't tell you whether you experience hypoglycemia. Gaining insight into what's affecting your blood sugar can help customize a diabetes management plan suited to your individual needs and routine.
Time in Range (TIR) is increasingly being used to assess blood sugar in combination with HbA1c. TIR is a measurement of how much of the day your blood sugar spends within your target range. It is measured as a percentage (%).3 The higher the TIR, the better the glucose control.
At least 70% of the day: 3.9 - 10 mmol/L
At least 50% of the day: 3.9 - 10 mmol/L
At least 70% of the day: 3.5 - 7.8 mmol/L
TIR
FreeStyle libre can show you the Time In Target you had in the last 7/14/30/90 days.
Type 1 or type 2
Patients who scanned more frequently had 43% higher TIR*11
HbA1c
Type 1
HbA1c reduced by 0.53% on average, after 12-16 weeks using FreeStyle Libre†27
Type 2
HbA1c reduced by 1.1% on average, after 22 weeks using FreeStyle Libre^27
*Comparing 2 groups from lowest to highest scan rate (3.6 and 39.5 scans/day), p=0.001.
†p<0.0001 vs. baseline
^in people using basal insulin, p<0.001 vs. baseline
References: 3. American Diabetes Association. Diabetes Care. 2020;43(1):S77–S88. 4. Battelino T, et al. Diabetes Care. 2019;42(8):1593–1603. 11. Evans M, et al Diabetes Ther. 2020;11(1):83–95. 24. Vigersky RA, et al. Diabetes Technol Ther. 2019;21(2):8–-85. 26. Wagner J, et al. Diabetes Technol Ther. 2005:7(4):612–9. 27. Wright E, et al. Diabetes Spectrum. 2021;34(2):184–189.
Disclaimers - 1. Images are for illustration purpose only. No actual patient data. Any person depicted in the photos is a model. Children shall not use without supervision. 2. The information mentioned in this document is only suggestive for patient education and shall not be considered as a substitute for doctor's advice or recommendations from Abbott. Please consult your doctor for more information.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.
Do you wish to continue and exit this website?
Stay connected